Overview

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
Assess the safety, tolerability and pharmacokinetics of multiple doses of 10, 20, 30, and 40 mg of Hydrocodone Bitartrate Extended Release (HC-ER)capsules taken with food at steady state, in subjects with chronic, moderate to severe osteoarthritis (OA) pain.
Phase:
Phase 2
Details
Lead Sponsor:
Zogenix, Inc.
Treatments:
Hydrocodone